OP0245

PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC

Dinesh Khanna¹, Celia J. F. Lin², Jonathan Goldin³, Grace Kim³, Masataka Kuwana⁴, Yannick Allanore⁵, Anastas Batalov⁶, Irena Butrimiene⁷, Patricia Carreira⁸, Marco Matucci-Cerinic⁹, Oliver Distler¹⁰, Dušanka Martinović Kaliterna¹¹, Carina Mihai¹², Mette Mogensen¹³, Marzena Olesińska¹⁴, Janet Pope¹⁵, Gabriela Riemekasten¹⁶, Tatiana Sofia Rodriguez-Reyne¹⁷, Maria Jose Santos¹⁸, Jacob M. van Laar¹⁹, Helen Spotswood²⁰, Jeffrey Siegel², Angelika Jahreis², Daniel Furst³, Christopher Denton²¹. ¹U Mich, Ann Arbor, United States of America; ²Genentech, South San Francisco, United States of America; ³UCLA, Los Angeles, United States of America; ⁴Nippon Med Sch, Tokyo, Japan; ⁵Paris Descartes U, Paris, France; ⁶Med U. Plovdiv, Plovdiv, Bulgaria; ⁷Vilnius U, Vilnius, Lithuania; ⁸Hosp Universitario, Madrid, Spain; ⁹U. Florence, Florence, Italy; ¹⁰U. Zurich, Zurich, Switzerland; ¹¹U. Split, Split, Croatia; ¹²Cantacuzino Hosp, Bucharest, Romania; ¹³Bispebjerg Hosp, Copenhagen, Denmark; ¹⁴Nat Inst Geriatic, Rheumatol, and Rehab, Warsaw, Poland; ¹⁵U. West Ontario, London, Canada; ¹⁶U Lubek, Charité U Hosp, Berlin, Germany; ¹⁷Inst Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; ¹⁸Hosp Garcia de Orta, Almada, Portugal; ¹⁹U. Med Ctr Utrecht, Utrecht, Netherlands; ²⁰Roche Products Ltd., Welwyn Garden City, United Kingdom; ²¹U. College London, London, United Kingdom

Background: The anti-IL6 receptor- α antibody tocilizumab (TCZ) demonstrated numerical improvement in modified Rodnan skin score (mRSS) and clinically relevant preservation of lung function (LF) (assessed by forced vital capacity [FVC]) in systemic sclerosis (SSc) patients (pts) in a ph 2 trial.¹

Objectives: Report the efficacy and safety (sft) of TCZ vs placebo (PBO) in SSc pts from the double-blind period of ph 3 trial (NCT02453256).

Methods: SSc pts were randomly assigned 1:1 to weekly subcutaneous TCZ 162 mg or PBO for 48 wks. Primary endpoint was mean difference (diff) in change (Δ) from baseline (BL) to wk 48 in mRSS for TCZ vs PBO. Key secondary endpoints were Δ BL%-predicted FVC (ppFVC) and time to Tx failure (time from first study treatment (Tx) to first occurrence of death, decline in FVC >10%, increase in mRSS >20% and mRSS ≥ 5 , or occurrence of predefined SSc-related Cx). Chest high-resolution computed tomography (HRCT) and ACR Combined Response in SSc (CRISS) were exploratory endpoints.

Results: Of 106 PBO- and 104 TCZ-treated pts, 81% were women and 31% had previous or concurrent interstitial lung disease based on history. BL mean values were age 48 yrs, SSc duration 23 mts, mRSS 20.4, ppFVC 82.1%, and ppDLCO 75.6%. Mean BL computer-assisted quantitative lung fibrosis of the most affected lobe (QLF-LM) was 4.7% for the PBO group and 5.5% for the TCZ group. At wk 48, the primary endpoint was not significant (Δ BL mRSS: PBO, -4.4; TCZ, -6.1; adjusted least squares mean diff, -1.7 [95% CI: -3.8, 0.3]; $p=0.098$) (Fig 1A). All p values for other endpoints were nominal. The cumulative distribution of wk 48 Δ BL ppFVC favored TCZ over PBO (median [IQR]: PBO, -3.9 [-7.2, 0.6] vs TCZ, -0.6 [-5.3, 3.9]; van Elteren nominal $p=0.0015$). The diff in mean Δ BL FVC at wk 48 between Tx groups was 167 mL (95% CI: 83, 250), favoring TCZ (Fig 1B). At wk 48, 5 (5.4%) TCZ-treated pts experienced $\geq 10\%$ absolute decline in ppFVC compared with 15 (16.5%) for PBO. The HR (95% CI) for time to Tx failure was 0.6 (0.4, 1.1), numerically favoring TCZ (Cox proportional hazards model; $p=0.082$). ACR CRISS scores favored TCZ over PBO at wk 48: median (IQR), 0.89 (0.09-1.00) vs 0.25 (0.00-0.99) ($p=0.023$). HRCT showed less progression of lung fibrosis for TCZ than for PBO, which supports the FVC results. Sft results were consistent with Cx of SSc and the established TCZ sft profile; SAEs were reported by 17% of PBO pts and 13% of TCZ pts; serious infections were reported by 7% and 2% of pts, respectively.

Figure 1. Change from baseline in (A) mRSS and (B) FVC

A mixed model for repeated measures analysis was implemented.

The analysis included the fixed, categorical effects of treatment, visit, the stratification factor IL-6 level (<10; ≥ 10 pg/mL) at screening, IL-6 level at screening-by-visit interaction, and treatment-by-visit interaction, as well as the continuous covariates of baseline score and baseline score-by-visit interaction. Includes 22 pts in the PBO group and 9 pts in the TCZ group who received immunomodulators from week 16 if they had FVC decline or from week 24 if they experienced worsened mRSS or worsened SSc complications.

Conclusion: The primary mRSS endpoint was not met; however, TCZ Tx resulted in clinically relevant differences in FVC with preservation of LFS and improvement in fibrosis, measured by HRCT, in SSc pts.

Disclosure of Interests: Dinesh Khanna Shareholder of: Eicos Sciences, Inc, Grant/research support from: Bayer, BMS, Pfizer, Horizon, Consultant for: Actelion Acceleron, Arena, Bayer, BI, BMS, CSL Behring, Corbus, Cytos, GSK, Genentech/Roche, Galapagos, Employee of: Elcos Sciences, Inc, Celia J. F. Lin Shareholder of: Genentech, Employee of: Genentech, Jonathan Goldin: None declared, Grace Kim Grant/research support from: Genentech, NHLBI, Consultant for: MedQIA LLC, Masataka Kuwana Grant/research support from: Actelion, Consultant for: Chugai, Reata, GlaxoSmithKline, Bayer, Boehringer-Ingelheim, Corpus, CSL-Berling, Mochida, Speakers bureau: Actelion, Pfizer, Bayer, Nippon Shinyaku, Chugai, Yannick Allanore Grant/research support from: Inventiva, F Hoffman La-Roche, Sanofi, BMS, Pfizer, Consultant for: Actelion, Bayer, BMS, Boehringer, Roche, Sanofi, Anastas Batalov: None declared, Irena Butrimiene: None declared, Patricia Carreira: None declared, Marco Matucci-Cerinic Grant/research support from: Actelion, MSD, Pfizer, BMS, Chemomab, Sanipedia, Speakers bureau: Actelion, BMS; MSD, Janssen, Oliver Distler Grant/research support from: Prof. Distler received research funding from Actelion, Bayer, Boehringer Ingelheim and Mitsubishi Tanabe to investigate potential treatments of scleroderma and its complications, Consultant for: Prof. Distler has/had consultancy relationship within the last 3 years with Actelion, AnaMar, Bayer, Boehringer Ingelheim, ChemomAb, espeRare foundation, Genentech/Roche, GSK, Inventiva, Italfarmaco, iQvia, Lilly, medac, MedImmune, Mitsubishi Tanabe Pharma, Pharmacyclics, Novartis, Pfizer, Sanofi, Serodapharm and UCB in the area of potential treatments of scleroderma and its complications. In addition, he had/had consultancy relationship within the last 3 years with A. Menarini, Amgen, Abbvie, GSK, Mepha, MSD, Pfizer and UCB in the field of arthritides and related disorders, Dušanka Martinović Kaliterna: None declared, Carina Mihai Consultant for: Received consulting fees or other remuneration from Actelion, Geneva, Roche, and Rofarm, Consultant for: F. Hoffmann-La Roche, Actelion, Geneva Romfarm, Mette Mogensen: None declared, Marzena Olesińska Consultant for: F. Hoffmann-La Roche, Janet Pope Consultant for: Eli Lilly and Company, Gabriela Riemekasten Consultant for: Chugai, F. Hoffmann-La Roche, Speakers bureau: Chugai, F. Hoffmann-La Roche, Tatiana Sofia Rodriguez-Reyne Grant/research support from: F. Hoffmann-La Roche, Maria Jose Santos: None declared, Jacob M. van Laar Grant/research support from: Genentech, Consultant for: F. Hoffmann-La Roche, Helen Spotswood Shareholder of: Roche Products Ltd., Employee of: Roche Products Ltd., Jeffrey Siegel Shareholder of: Genentech, Consultant for: Genentech, Angelika Jahreis Shareholder of: F. Hoffmann-La Roche, Employee of: Genentech, Daniel Furst Grant/research support from: F. Hoffmann-La Roche, Genentech, Christopher Denton Grant/research support from: GlaxoSmithKline, Inventiva, CSF Behring, Consultant for: Roche-Genentech, Actelion, GlaxoSmithKline, Sanofi Aventis, Inventiva, CSL Behring, Boehringer Ingelheim, Bayer

DOI: 10.1136/annrheumdis-2019-eular.2120

FRIDAY, 14 JUNE 2019

SLE news

OP0246

ATTAINMENT OF THE LUPUS LOW DISEASE ACTIVITY STATE IS ASSOCIATED WITH PROTECTION FROM DAMAGE ACCRUAL IN PATIENTS WITH ACTIVE DISEASE AT BASELINE

Vera Golder^{1,2}, Eric F. Morand^{1,2}, Rangi Kandane-Rathnayake^{1,2}, Molla Huq³, Hieu Nim¹, Worawit Louthrenoo⁴, Shue Fen Luo⁵, Yeong-Jian Wu⁵, Aisha Lateef⁶, Sargunan Sockalingam⁷, Sandra Navarra⁸, Leonid Zamora⁸, Laniyati Hamijoyo⁹, Yasuhiro Katsumata¹⁰, Masayoshi Harigai¹⁰, Madelynn Chan¹¹, Sean O'Neill¹², Fiona Goldblatt¹³, Chak Sing Lau¹⁴, Li Zhanguo¹⁵, Alberta Hoi^{1,2}, Mandana Nikpour³, Asia Pacific Lupus Collaboration. ¹Monash University, Clayton Campus, Clayton, Australia; ²Monash Medical Centre, Clayton, Australia; ³University of Melbourne, Parkville, Australia; ⁴Chiang Mai University, Chiang Mai, Thailand; ⁵Chang Gung Memorial Hospital, Guishan, Taiwan, Republic of China; ⁶National University Hospital, Singapore, Singapore; ⁷University of Malaya, Kuala Lumpur, Malaysia; ⁸University of Santo Tomas Hospital, Manila, Philippines; ⁹Padjadjaran University, Bandung, Indonesia; ¹⁰Tokyo Women's Medical University, Shinjuku, Japan; ¹¹Tan Tock Seng Hospital, Singapore, Singapore; ¹²Liverpool Hospital School, Liverpool, Australia; ¹³West Terrace, Adelaide, Australia; ¹⁴University of Hong Kong, Hong Kong, Hong Kong (SAR); ¹⁵Peking University, Beijing, China

Background: The recently validated Lupus Low Disease Activity State (LLDAS) definition has been shown to have utility as a treat to target endpoint in SLE, whereby LLDAS attainment is associated with reduction in permanent damage accrual. Robust evaluation is required to ensure this protective association is not simply reflective of milder disease phenotypes being over-represented among LLDAS attainers.

Objectives: To assess the effect of attainment of LLDAS on damage accrual in patients with active disease at baseline. SLEDAI-2K_{≥6} was chosen as this reflects clinical trial entry criteria.

Methods: A prospective multinational cohort study was undertaken in 13 centres between 2013-2017. Patients with SLE were recruited, SLEDAI-2k, SELENA flare index, PGA, and medication data collected at every visit, and damage score (SLICC-ACR damage index (SDI)) collected annually. Subgroup analyses were performed to assess the effect of LLDAS on damage accrual in patients who had active disease at baseline (SLEDAI-2K_{≥6}). Time-dependent hazards regression models were used to assess the association of attainment of LLDAS at any time point, and proportion of time in LLDAS at the 50% observed time cut-off, with accrual of irreversible end-organ damage.

Results: 1,735 patients were followed for (mean ± SD) 2.2 ± 0.9 years, totalling 12,717 visits. LLDAS attainment was less frequent in patients with active disease at baseline (901 of 3835 visits in LLDAS, 23.5%), compared to patients with SLEDAI-2K_{<6} at baseline (5190 of 8845 visits in LLDAS, 58.7%), p<0.001. In contrast, compared to those with baseline SLEDAI-2K_{<6}, patients with active disease at baseline demonstrated a stronger association of LLDAS attainment with reduction in risk of damage accrual, in visit by visit analysis (HR 0.49, 95% CI 0.28-0.86, p 0.01 vs HR 0.72, 95% CI 0.52-0.99, p 0.05), and in analysis of cumulative time spent in LLDAS (HR 0.52, 95% CI 0.33-0.83, p 0.01 vs HR 0.65, 95% CI 0.47-0.91, p 0.01).

Conclusion: Despite lower attainment of LLDAS in patients with higher disease activity at baseline, the magnitude of association of LLDAS attainment with lower damage accrual was greater in this subgroup of patients compared to those less active baseline disease. This supports the validity of LLDAS as an outcome measure, in a population similar to that typically selected into clinical trials, and further highlights the potential impact of achieving a target outcome in SLE patients with active disease.

Disclosure of Interests: Vera Golder: None declared, Eric F. Morand Grant/research support from: AstraZeneca, Bristol Myers Squibb, Janssen, Merck Serono, and UCB, Consultant for: AstraZeneca, Eli Lilly, Janssen, and Merck Serono, Speakers bureau: AstraZeneca, Rangi Kandane-Rathnayake: None declared, Molla Huq: None declared, Hieu Nim: None declared, Worawit Louthrenoo: None declared, Shue Fen Luo: None declared, Yeong-Jian Wu: None declared, Aisha Lateef: None declared, Sargunan Sockalingam: None declared, Sandra Navarra: None declared, Leonid Zamora: None declared, Laniyati Hamijoyo: None declared, Yasuhiro Katsumata: None declared, masayoshi harigai Grant/research support from: Tokyo Women's Medical University (TWMU) has received unrestricted research grants for Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases from Ayumi Pharmaceutical Co. Ltd., Bristol Meyers Squibb, Chugai Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp., and with which TWMU paid the salary of MH. MH has also received research grants from AbbVie Japan GK, Eisai Co. Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd., Madelynn Chan: None declared, Sean O'Neill: None declared,

Fiona Goldblatt: None declared, Chak Sing Lau: None declared, Zhanguo Li: None declared, Alberta Hoi Grant/research support from: GSK, AstraZeneca, UCB and Merck Serono, Consultant for: Janssen Steering Committee, Speakers bureau: Novartis, Mandana Nikpour: None declared
DOI: 10.1136/annrheumdis-2019-eular.4457

OP0247

EFFECT OF IMMUNOSUPPRESSIVE DRUG WITHDRAWAL ON DAMAGE PROGRESSION AND FLARE OCCURRENCE IN SLE PATIENTS IN REMISSION

Margherita Zen, Francesca Saccon, Mariele Gatto, Maddalena Larosa, Francesco Benvenuti, Luca Iaccarino, Andrea Doria. University of Padova, Rheumatology Unit – Department of Medicine (DIMED), PADOVA, Italy

Background: Patients with Systemic Lupus Erythematosus (SLE) are often treated with prolonged maintenance therapy with immunosuppressants (ISs) after remission achievement, with the aim of avoiding disease flares and subsequent organ damage. Data on the risk of flare after IS discontinuation and the effect of IS discontinuation on damage accrual are scanty.

Objectives: Our aims were to analyze damage progression in remitted SLE patients who did or did not discontinued ISs, to assess flare rate after IS withdrawal and to compare damage accrual in patients who did or did not flare after IS discontinuation.

Methods: We considered all SLE patients included in our lupus database, diagnosed between 1990 and 2018 (ACR criteria), treated with immunosuppressants over their disease course, who discontinued IS due to remission. IS discontinuation was defined as complete withdrawal of any immunosuppressive drug, and remission as clinical SLE Disease Activity Index (SLEDAI)-2K=0. Flares were defined according to SLEDAI Flare Index, and damage according to SLICC damage Index (SDI).

Results: Eligible patients ever treated with ISs were 319 out of 456 (69.9%) currently in follow-up. Remission lasting at least 6 months was achieved by 206 patients treated with IS (64.6%) (Table 1); among them 105 (51%) discontinued ISs during the follow-up. Mean±SD follow-up after IS withdrawal was 91±71 months (range 6-372). No difference in damage accrual between remitted patients who discontinued or did not discontinue ISs was observed at the end of follow-up, after adjusting for disease duration: median (range) SDI 1 (0-6) and 0 (0-4), respectively. Accordingly, the proportion of remitted patients who accrued damage during the follow-up was similar between those who did or did not discontinue ISs (55% vs. 48%). Among patients who discontinued ISs, 26 (24.7%) experienced a flare after a median (range) of 57 (6-264) months from IS discontinuation. Flares were severe in 50% of cases (Table 2). No difference in damage progression between patients who flared and did not flare after IS withdrawal was found at the end of follow-up: median (range) SDI 1 (0-5) and 1 (0-6), respectively. Moreover, the proportion of patients with damage accrual was similar among patients with and without flare after IS discontinuation (56% vs. 54%).

Table 1. Characteristics of remitted patients according to the discontinuation of ISs. Data are expressed as mean±SD or number (%).

	Remitted patients		P value
	IS discontinued (105)	IS not discontinued (101)	
Female, N (%)	93 (88.6)	85 (84.1)	n.s.
Age at 2018, years	44±11	40±12	0.035
SLE duration at 2018, years	19.5±9.2	12.3±8.7	0.027
SLE duration at remission, years	5.2±6.1	6.3±4.2	n.s.
Remission lasting at IS discontinuation > 2 consecutive years, N (%)	66 (63)	36 (35.6)	0.001
Reason for IS therapy, N (%)			
Lupus Nephritis	68 (64.8)	57 (56.4)	n.s.
Skin involvement	6 (5.7)	7 (6.9)	
Arthritis	12 (11.4)	15 (14.4)	
Haematological involvement	5 (4.7)	8 (7.9)	
Neuropsychiatric involvement	3 (2.9)	2 (1.9)	
Vasculitis	3 (2.9)	1 (0.9)	
Multisystemic involvement	8 (7.6)	11 (11)	
Type of last IS*, N (%)			
Mycophenolate	48 (45.7)	73 (72.2)	0.001
Azathioprine	30 (28.6)	18 (17.8)	0.04
Methotrexate	14 (13.3)	5 (4.9)	0.008
Cyclosporine	7 (6.7)	4(3.9)	n.s.
Cyclophosphamide	6 (5.7)	1 (0.9)	0.001

* last IS used before withdrawal or at last visit. Multisystemic: involvement of more than 2 organs requiring IS therapy.